Printed from http://www.researchandmarkets.com/reports/2204695
Algeria Pharmaceuticals and Healthcare Report Q3 2012
BMI View: With the push into emerging markets by pharmaceutical companies and the dangers of importing drugs into the Algerian market well documented, it makes sense that large multinational drugmakers would want to partner with local companies. High rates of foreign direct investment in the past year also indicate that the Deloitte Vision 2012 report on the viability of using Algeria as a hub for the production of biologics was a success, and its recommendations have been at least internalised by the Algerian government. However, interestingly it is European drugmakers that are making moves in the country, while the Deloitte report was supposed to assist US drugmakers entering the market.
Headline Expenditure Projections:
- Pharmaceuticals: DZD218.5bn (US$3.00bn) in 2011 to DZD233.9bn (US$3.12bn) in 2012; +7.0% in local currency terms and +4.0% in US dollar terms. Forecast up marginally from Q112.
- Healthcare: DZD531.3bn (US$7.29bn) in 2011 to DZD565.1bn (US$7.54bn) in 2012; +6.4% in local currency terms and +3.4% in US dollar terms. Forecast down moderately from Q212 due to new historic data.
- Medical devices: DZD28.3bn (US$388mn) in 2011 to DZD30.11bn (US$401mn) in 2012; +6.6% in local currency terms and +3.5% in US dollar terms. Forecast down slightly from Q112 due to foreign exchange considerations.
Risk/Reward Ratings: In Q212, Algeria’s overall score has risen slightly, but the country remains 12th out of the 30 regional markets surveyed in the expanded Middle East and Africa (MEA) matrix. Its composite score rose by 1.5 points quarter-on-quarter and stands at a modest 46.6 out of 100, compared with the regional average of 44.5.
Key Trends And Developments: - In April 2012, Novo Nordisk signed a partnership with state-backed drugmaker Saidal Laboratories. In the same month, AstraZeneca agreed to collaborate with local private pharmaceutical company Biopharm. With the opening of Hikma's second production facility in the country in 2011 and the US drugmaker Amgen announcing plans to open a production facility, it is apparent that the Algerian market is becoming increasingly attractive for multinational drugmakers.
- Abdi Ibrahim is set to expand to new markets by establishing operations and partnerships with local firms in the Middle East, North Africa and Central Asia. Chief executive Candan Karabagli told Hurriyet Daily News the company plans to create new operations and partnerships in Iraq, Saudi Arabia, Algeria and Kazakhstan over the next few years.
BMI Economic View: Algeria's current account is set to stay firmly in the black over the medium term.
We forecast the current account surplus to come in at 10.8% and 8.1% of GDP in 2012 and 2013 respectively, from 11.2% in 2011. Moreover, although the financial account fell from US$3.4bn to -US$1.2bn in 2011, regulatory developments in the energy sector bode well for the outlook over the next few years. As a result, the country's current external position looks solid over the medium term, and is underpinned by healthy foreign reserves, which are equivalent to approximately 50 months of import coverage.
BMI Political View: Legislative elections will take place in Algeria on May 10, but we do not see them changing the political status quo in 2012. In an effort to strengthen the regime's legitimacy, international monitors have been invited, and 18 additional parties have been allowed to participate, for a total of 42.
Nonetheless, parliament holds much less power than the executive, and due to a general disillusionment in the political process, coupled with the government's willingness to increase social spending to appease discontent, we believe the risks of widespread unrest erupting alongside the election are low. That said, a good electoral showing for opposition parties could increase medium-term risks for the regime, highlighting its unwillingness to share power even as popular support wanes. This could trigger further discontent, particularly at the outset of presidential elections scheduled for April 2014.
SWOT Analysis 7
Algeria Pharmaceuticals And Healthcare Industry SWOT 7
Algeria Political SWOT 8
Algeria Economic SWOT 8
Algeria Business Environment SWOT 9
Pharmaceutical Risk/Reward Ratings 10
Table: Pharmaceuticals & Healthcare Q312 Risk/Reward Ratings 11
Algeria – Market Summary 17
Regulatory Regime 19
Trade Agreements 21
Intellectual Property Environment 22
Intellectual Property Shortcomings 22
Pricing And Reimbursement Regime 25
Industry Trends And Developments 27
Communicable Diseases 28
Non-Communicable Diseases 29
Healthcare Sector 30
Healthcare Sector Reforms 32
Biotechnology And Research 33
Medical Devices 35
Industry Forecast Scenario 36
Overall Market Forecast 36
Table: Pharmaceutical Sales Indicators 2008-2016 38
Key Growth Drivers – Industry 39
Table: Healthcare Expenditure Indicators 2008-2016 40
Table: Healthcare Governmental Indicators 2008-2016 40
Table: Healthcare Private Indicators 2008-2016 41
Key Growth Factors – Macroeconomic Forecast 42
Table: Algeria – Economic Activity, 2011-2016 45
Prescription Drug Market Forecast 46
Table: Prescription Drug Sales Indicators 2008-2016 47
Patented Drug Market Forecast 48
Table: Patented Drug Market Indicators 2008-2016 49
Generic Drug Market Forecast 50
Table: Generic Drug Sales Indicators 2008-2016 51
OTC Medicine Market Forecast 52
Table: OTC Medicine Sales Indicators 2008-2016 53
Medical Device Market Forecast 54
Table: Medical Devices Sales Indicators 2008-2016 55
Pharmaceutical Trade Forecast 56
Table: Exports and Imports Indicators 2008-2016 57
Other Healthcare Data Forecasts 58
Key Risks To our Forecast Scenario 58
Competitive Landscape 59
Pharmaceutical Industry 59
Domestic Pharmaceutical Sector 59
Domestic Pharmaceutical Sector Developments 61
Foreign Pharmaceutical Sector 62
Recent Foreign Pharmaceutical Sector Developments 63
Pharmaceutical Wholesale 66
Pharmaceutical Retail 67
Company Profiles 68
Local Companies 68
Groupe Saidal 68
Multinational Companies 70
Merck & Co 77
Demographic Outlook 78
Algeria's Population By Age Group, 1990-2020 ('000) 79
Algeria's Population By Age Group, 1990-2020 (% of total) 80
Algeria's Key Population Ratios, 1990-2020 81
Algeria's Rural And Urban Population, 1990-2020 81
BMI Methodology 84
How We Generate Our Pharmaceutical Industry Forecasts 84
Pharmaceutical Risk/Reward Ratings Methodology 85
Ratings Overview 85
Table: Pharmaceutical Risk/Reward Indicators 86
Table: Weighting Of Components 87
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Research and Markets,
Fax order form
To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email firstname.lastname@example.org
Please verify that the product information is correct and select the format you require.
Algeria Pharmaceuticals and Healthcare Report Q3 2012
Please enter the quantity of the report format you require.
|Electronic (PDF) - Single User||EUR 894|
Please enter all the information below in block capitals.
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Please indicate the payment method you would like to use by selecting the appropriate box.
Please post the check, accompanied by this form, to:
Research and Markets,
Please transfer funds to:
27-35 Main Street
If you have a Marketing Code please enter it below:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp